Late-onset Stevens–Johnson syndrome due to nivolumab use for hepatocellular carcinoma

Pembrolizumab-induced Stevens–Johnson syndrome in non-melanoma patients

(2017) Stephanie Saw et al.   EUROPEAN JOURNAL OF CANCER

Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor

(2017) Liting Guo et al.   Journal of Cancer

CTLA-4 and PD-1 Pathways

(2016) Elizabeth I. Buchbinder et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy

(2016) Simone M. Goldinger et al.   CLINICAL CANCER RESEARCH

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

(2015) Scott N. Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY